Synchrotron Beamtime-as-a-Service: Market Overview
Global market sizing, growth trajectory, and pricing benchmarks
Data sourced from market research reports and facility documents. Some figures are from commercial market reports (not independently audited). Use as directional benchmarks.
Global Synchrotron Market (2025)
$1.5B
Total market value USD
+9.2% CAGR
Projected Market (2034)
$3.2B
9-year forecast
2.1x growth
Proprietary Beamtime Rate
$790
Per hour, NSLS-II FY2026
+2 hr minimum
Industrial Share of Users
~5%
ESRF 2011-2021 (non-academic)
Large white space
Market Segments by Instrumentation Demand
Source: Future Market Insights synchrotron instrumentation report, 2025. Pharma/aerospace estimated from combined sources.
Strategic Observations
Large untapped industrial market
Only ~5% of ESRF users come from industry despite clear demand. Most companies never reach beamtime due to access friction, not lack of need.
Pharma is the anchor vertical
AstraZeneca alone generates ~800 unique protein-ligand structures per year. Drug discovery is the most mature and high-volume industrial use case.
9.2% CAGR through 2034
The market is nearly doubling in under 10 years. Battery technology, advanced alloys, and semiconductor scaling are driving new industrial demand.
Pricing benchmark: $790/hr
NSLS-II full cost-recovery proprietary rate. Scatterin positions as comparable to lab-scale cost at synchrotron quality, which is our same opportunity.
Target Industry Verticals
Who buys beamtime and why, with confirmed industrial users at DESY
Pharmaceutical & Biotech
Highest volume user
Structural biology for drug discovery. AstraZeneca: ~800 protein-ligand structures/year. ESRF MXpress was built specifically for pharma mail-in service.
DESY confirmed clients
BioNTech (Ugur Sahin personally published SAXS work at PETRA III) and Captor Therapeutics are named DESY users.
Best-fit pitch: fastest path to structural data, no queue.
Aerospace & Advanced Manufacturing
Materials under stress
Fatigue analysis, weld integrity, composite microstructure. Beamtime reveals what CT and lab X-ray cannot at component scale.
Confirmed users
GKN Aerospace and OHB at DESY. Rolls-Royce and Airbus at Diamond and ESRF. TRUMPF using DESY for e-car copper welding.
Best-fit pitch: time-resolved in-situ measurements during mechanical loading.
Energy, Batteries & Semiconductors
Fastest growing segment
Li-ion battery development, hydrogen fuel cells, and catalyst research. Operando XRD during charge/discharge is growing demand. Johnson Matthey invested in Diamond specifically for fuel cells.
Semiconductors: real named users
STMicroelectronics has 4+ named researchers actively publishing ESRF beamtime work on phase-change memory and 3D IC characterisation.
Best-fit pitch: in-situ experiments under real operating conditions.
Confirmed Industrial Users at DESY PETRA III
BioNTech SE
Pharma / mRNA therapeutics
SAXS at PETRA III P12 — Ugur Sahin co-authored
SAXS at PETRA III P12 — Ugur Sahin co-authored
Captor Therapeutics
Drug discovery
Macromolecular crystallography at PETRA III
Macromolecular crystallography at PETRA III
GKN Aerospace
Aerospace components
Industrial measurements at PETRA III
Industrial measurements at PETRA III
OHB System AG
Space / satellite manufacturing
Industrial measurements at PETRA III
Industrial measurements at PETRA III
Hilti AG
Power tools / fastening systems
Materials characterisation at PETRA III
Materials characterisation at PETRA III
TRUMPF
Laser manufacturing / automotive
In situ X-ray imaging of EV copper welding at P07
In situ X-ray imaging of EV copper welding at P07
Beiersdorf AG
Consumer / cosmetics
XRF nano-imaging at P06
XRF nano-imaging at P06
Haldor Topsoe
Chemicals / catalysts
XAS/XRD catalyst characterisation
XAS/XRD catalyst characterisation
SKF
Bearings / industrial
Bearing materials research
Bearing materials research
Customer Pain Points
Why industrial companies do not access beamtime directly — documented barriers from NSLS-II industry workshop and UKRI/ESRF impact reports
Unfamiliarity with synchrotron techniques
Most industrial R&D teams have never run a synchrotron experiment. They do not know what is measurable, what beamline to choose, or how to prepare samples.
No in-house expertise
Industrial teams lack the specialist knowledge to write competitive proposals, design experiments, or process the data post-collection.
Long lead times
Open-access beamtime is allocated competitively by review panels meeting 2-3 times per year. Industrial product cycles cannot wait 6-12 months for a slot.
High cost and payment terms
NSLS-II charges $790/hr with a 2-hour minimum and requires 100% advance payment. Without pre-existing relationships, the financial commitment is hard to justify.
Legal concerns with user agreements
Facility user agreements contain IP clauses that industrial legal teams find unfamiliar. Proprietary access routes require separate negotiations companies rarely know how to navigate.
No alternative instrument elsewhere
~70% of ESRF users said they could not pursue the same research without synchrotron access. There is no lab-scale substitute for many experiments.
Our Value Proposition
We close the expertise gap
We bring the synchrotron knowledge the client lacks. They describe their material problem; we design the experiment.
We eliminate queue time
Pre-booked beamtime and Wavegate technology cut experiment time and bypass competitive allocation queues. Results in weeks, not months.
We handle legal and admin
We hold the facility agreements. The client signs one contract with us, not a 30-page facility user agreement.
We prove the value first
The strongest sales motion is a pilot result. Show the client something they could not see before. The data sells the next project.
LinkedIn post angle
The time-resolution post targets engineers and R&D leads who have a materials problem but have never considered synchrotron. The post is the top of funnel. The pain points above are what the sales conversation closes on.
Competitive Landscape
Known providers offering commercial synchrotron or beamtime-as-a-service
Scatterin AB is the most direct known competitor to our model. Others are sector-specific CROs. Facility-run programmes represent the status quo we are replacing.
Scatterin AB
Stockholm, Sweden — KTH spinoff • CEO: Ahmet Bahadir Yildiz
Pre-booked commercial access to European synchrotron and neutron facilities. End-to-end Measurement-as-a-Service: planning, sample prep, beamtime, and SaaS-delivered analysis. 1-2 week turnaround. Claims cost parity with lab-scale solutions. Confirmed clients: Hilti, Volvo Cars, Sandvik.
Closest match to usEuropean focus2-10 employees
Company
Founded28 July 2021. KTH Royal Institute of Technology spinoff via KTH Innovation + KTH Ventures.
CEOAhmet Bahadir Yildiz — PhD Materials Science KTH / RWTH Aachen
CSOProf. Peter Hedstrom — KTH Professor, Director of CeXS and NEXT competence centre
Team size~7 people; Hamburg-based synchrotron expert (ex-DESY P21.2 beamline scientist 2020-2024)
FundingKTH Ventures (equity, Aug 2023); Vinnova grants SEK 2.55M confirmed; Ready2Scale EUR 60k (EU Horizon). Pre-seed, no VC round identified.
Tagline"Deeper insight. Faster loops. Better materials."
PricingNo public pricing. Claims "similar cost as lab-scale solutions" — unverified. All quotes bespoke.
Confirmed Facilities
DESY PETRA III (Hamburg) — P07 (online analysis 2 patterns/sec, Jul 2024) + P21.2 Swedish Materials Science beamline
MAX IV (Lund, Sweden) — live diffraction SaaS tested Jan 2026
ISIS (Didcot, UK) — neutron diffraction; Sandvik project Feb 2025
ESS (Lund) — listed as MAXESS industry partner; no public ESS case study yet
ESRF, Diamond, ILL: not publicly confirmed
Techniques
Synchrotron XRD (residual stress, strain gradients)
SAXS (minority phases, precipitates below 1 vol%)
XANES / EXAFS
Imaging, radiography, tomography (sub-micron)
Neutron diffraction (3D stress mapping, cm-depth in steel)
SANS
In-situ / operando (sub-second time resolution)
Bundled: SEM, TEM, EBSD (not confirmed in-house)
Target Verticals
Automotive (Volvo Cars — HPDC megacasting residual stress)
Tooling / advanced alloys (Sandvik, Hilti)
Aerospace
Energy systems (Hitachi Energy — NEXT Consortium)
Additive manufacturing, bearing steel
Pharma, battery, semiconductors: NOT marketed
Service Model
1. Plan
Define objectives, technique + facility selection
→
2. Prepare
Sample prep, custom environments, safety compliance
→
3. Measure
Pre-booked beamtime at European facilities
→
4. Deliver
SaaS platform analysis, results in 1-2 weeks
Their Differentiators (claimed)
Proprietary "Scatterin Platform" SaaS — live analysis at 2 patterns/sec during beamtime
Both synchrotron and neutron access from one provider
Pre-booked slots — no proposal writing, no queue
100% data confidentiality; client owns all results
Weaknesses vs Us
No Wavegate equivalent — no proprietary experiment time compression
Very small team (2-10) — capacity constraints at scale
No pharma, battery, or semiconductor vertical — large market gap
No confirmed ESRF or Diamond access — limited southern/UK coverage
Pricing opaque — "lab-scale cost" claim unverified
Recent Activity (2024-2026)
Feb 2026 — Volvo Cars HPDC megacast residual stress case study; FEM prediction validation
Jan 2026 — Live diffraction SaaS tested at MAX IV (fiber orientation analysis)
Jul 2025 — Hilti AG drill bit case study; Chief Scientist Steven Moseley quoted publicly
Feb 2025 — Sandvik cutting tool neutron diffraction at ISIS (Cr-doped hard metals)
Nov 2024 — Vinnova SEK 2M grant for product-market fit acceleration (runs to Mar 2026)
Nov 2023-2024 — ESAB partnership; in-situ XRD of high-strength steel welds at DESY PETRA III
Jul 2024 — DESY P07 SaaS pipeline: 2 diffraction patterns/sec live analysis confirmed
2023 — Brogren Industries + RISE aerospace engine components at PETRA III (Vinnova aviation grant)
Additional named clients: Ovako AB (bearing steel at PETRA III); Hitachi Energy (NEXT Consortium)
Momentum Transfer
Hamburg, Germany — DESY / BASF spinout
Commercial X-ray scattering data services, co-founded by DESY and BASF veterans. The BASF-to-Momentum-Transfer move by CSO Hinrichsen is the strongest public signal that industrial demand for this service is real.
Emerging competitorBASF / DESY pedigree
Company
Founded2023, Hamburg. Registered: District Court of Hamburg HRB 193795. Incubated via Chemovator (BASF's venture studio).
CEODr. Sebastian Winkler — synchrotron veteran
CSODr. Bernd Hinrichsen — 13 yrs BASF (Research Manager, XRD/SEM/TEM/NMR labs), ex-Bruker AXS, PhD MPI Stuttgart (Dinnebier lab)
COODr. Maxwell Terban — PDF specialist; ex-MPI Stuttgart (Dinnebier lab); PhD Columbia/BNL; h-index 30; 4,053 citations
Sci. AdvisoryProf. Simon Billinge (Columbia/BNL) and Prof. Robert Dinnebier (MPI Stuttgart) — direct PhD mentors of co-founders
FundingIFB (Investitionsbank Hamburg) grant, September 2025. Prior incubation via Chemovator (BASF venture studio).
Techniques and Facility
Beamline P25, DESY PETRA III (Hamburg) — confirmed operational base
Synchrotron powder X-ray diffraction (PXRD) — high-throughput
Total scattering and PDF (pair distribution function) — Terban's world-class specialism
Battery materials characterisation — the origin use case from BASF R&D
Catalysts, polymers, coatings, pigments, amorphous/nanostructured materials
Target Verticals
Battery / energy materials (born from BASF's battery crystal structure needs)
Chemicals and catalysis (Hinrichsen's BASF base; ESRF STREAMLINE co-design)
Advanced materials: polymers, coatings, nanostructured systems
Pharmaceuticals — Terban published on drug structure; likely a vertical
Weaknesses vs Us
One confirmed facility (DESY P25) — geographically concentrated in Hamburg
Technique narrow: PXRD / total scattering / PDF — no imaging, no MX, no neutrons (inferred)
No Wavegate equivalent — no proprietary experiment compression
Founded 2023 — very limited public case study track record
Website sparse; no published pricing or turnaround times
Strategic Signal
Hinrichsen spent 13 years at BASF managing central characterisation labs before leaving to co-found this. BASF co-designed ESRF's STREAMLINE powder diffraction service — he knows exactly what industrial demand looks like from the inside. That he saw the opportunity as large enough to leave one of the world's largest chemical companies is the single strongest independent validation of our market. Their BASF proximity also creates an acquisition angle: if Momentum Transfer grows, BASF or a similar industrial conglomerate is the obvious buyer.
SARomics Biostructures AB
Lund, Sweden — Pharma structural biology CRO
Fragment screening and protein-ligand structure determination services for pharma drug discovery. Uses MAX IV and ESRF. CEO Bjorn Walse; CSO Derek Logan sits on the European Synchrotron and FEL User Organisation board.
Pharma vertical onlyPotential partner
Company
Founded2006 by 5 Lund University scientists. Based at Medicon Village since 2012, Lund (org. nr 556688-4150)
FoundersBjorn Walse, Derek Logan, Mikael Akke, Salam Al-Karadaghi, Bo Svensson
CEOBjorn Walse — co-founder, structural biologist
CSODerek Logan — co-founder, Associate Professor Lund University, ESUO board member
Size27 employees (Swedish registry); 21 visible on LinkedIn
Funding6 rounds, 8 investors (last round Sep 2017). Investors: Innovationsbron, LU Innovation System, Almi Invest, SmiLe, Sparbanken Skåne, LU Holding, European Investment Fund. No recent VC round identified.
RecentApr 2026: commercial partnership with Accelero Biostructures (San Francisco) — no equity change
PricingNo public pricing. Project-based quotes for pharma clients.
Facilities
MAX IV (Lund) — primary; started at predecessor MAX II; on-site proximity advantage
ESRF (Grenoble) — MX beamlines for structure determination
Diamond (Harwell, UK) — likely used (unconfirmed)
Services and Techniques
Macromolecular X-ray crystallography (MX)
Fragment-based drug discovery (FBDD) screening
Protein-ligand structure determination
SAXS for protein characterisation
Crystal optimisation and compound soaking
Target Verticals
Pharma drug discovery (Top 20 Big Pharma + biotech)
Fragment-to-lead programmes
Academic / non-profit research collaborations
No industrial/materials/energy vertical
Their Differentiators
20 years of operation — established pharma track record
MAX IV founding-era proximity — started at MAX II, co-evolved with the facility
CSO Derek Logan on ESUO board — direct facility governance relationships
Accelero Biostructures (SF) partnership — US pharma market reach (Apr 2026)
Weaknesses vs Us / Partnership Angle
Pharma only — zero presence in materials, energy, aerospace, automotive
No Wavegate equivalent — no time compression technology
Funding stalled since 2017 — limited growth capital for expansion
Partnership angle: SARomics handles pharma MX, we handle all other verticals and techniques — clean referral boundary
Recent Activity (2024-2026)
Apr 2026 — Commercial partnership with Accelero Biostructures (San Francisco) — US pharma market entry signal
Sep 2025 — FBLD 2025 (Cambridge): poster "A Platform for Efficient X-Ray Crystallography-Based Fragment Screening and Hit Evolution of Kinase Targets" — 15 SARomics authors + MAX IV collaboration
Apr 2024 — Drug Discovery Chemistry (San Diego): CEO Bjorn Walse oral presentation + poster on WAC fragment screening of IL-23
Nov 2023 — Multiple posters at PEGS Europe (Lisbon); Festival of Biologics (Basel)
Proteros Biostructures GmbH
Munich, Germany — Large-scale structural biology CRO
Commercial X-ray crystallography and cryo-EM serving most Top 20 Big Pharma. Spun out of Max Planck Institute of Biochemistry. CEO Dr. Torsten Neuefeind. Largest and most established pharma structural CRO in Europe.
Pharma vertical onlyPotential partner
Company
Founded1999/2001, spinout from Max Planck Institute of Biochemistry (Nobel laureate Prof. Robert Huber lab), Martinsried
OwnershipAcquired by Inflexion Private Equity — growth/exit orientation
CEODr. Torsten Neuefeind — founder; PhD TU Munich (Huber lab); ex-McKinsey, Bayer
CBORyan Brady — 20+ yrs biopharma BD; ex-Evotec
CSODr. Horst Hemmerle — ex-Novartis, Eli Lilly, Aventis
Clients18 of the 20 largest global pharma companies; 250+ biotech partners across US, Europe, Japan
Scale700+ structures/year; 7,000+ total solved; 25+ structural biologists; 200+ Gallery Structures
Services and Techniques
Protein X-ray crystallography (MX) — core service; proprietary Free Mounting System (FMS)
Cryo-electron microscopy (cryo-EM)
Fragment-based drug discovery (FBDD); proprietary Picodropper soaking technology
Protein production, crystallisation, biochemical / biophysical assays
iLead integrated medicinal chemistry programme
Gallery Structures: 200+ pre-established targets for fast client access
Their Differentiators
Nobel Prize scientific heritage (Robert Huber, MPI) — strongest trust signal in the market
90%+ project success rate claimed; 700+ structures/year at scale
Proprietary FMS + Picodropper — hardware IP differentiates from all competitors
Full pipeline CRO: protein to structure to chemistry under one roof
No royalties; full IP transfer to client
AstraZeneca oncology collaboration announced 2022
Weaknesses vs Us / Partnership Angle
Pharma only — zero presence in materials, energy, automotive, aerospace
No Wavegate equivalent — no time compression technology
PE-owned: pricing pressure and potential staff churn concerns some pharma buyers
Single Martinsried site — geographic concentration risk
No public pricing or turnaround benchmarks — high-friction sales entry
Partnership angle: overflow/specialist referral for pharma MX we cannot serve at their volume
Finden Ltd
Harwell, UK — XRD-CT industrial spinout
Specialists in XRD computed tomography for industrial materials. Antony Vamvakeros (Royal Society Industry Fellow) uses DESY PETRA III P07 and Diamond. 2023 RSC Analytical Science Horizon Prize. Direct overlap with our DESY access.
DESY P07 overlapPotential partner
Profile based on publicly known information — fresh web research pending (rate limit resets 12:40pm Berlin). Verify before using externally.
Company
LocationHarwell Science and Innovation Campus, UK
R&D LeadAntony Vamvakeros — Royal Society Industry Fellow, Imperial College London (confirmed LinkedIn)
Award2023 RSC Analytical Science Horizon Prize for XRD-CT work
AffiliationClose ties to Diamond Light Source (Harwell campus) and DESY Hamburg
PricingNo public pricing found
Facilities
DESY PETRA III P07 (Hamburg) — confirmed for industrial XRD-CT
Diamond Light Source (Harwell, UK) — on-site proximity; I12 JEEP likely
ESRF (Grenoble) — used in published research
Services and Techniques
XRD-CT (X-ray diffraction computed tomography) — core specialism
SAXS-CT and fluorescence-CT
nDTomo software (open-source data processing for XRD-CT)
In-situ / operando tomography under reaction conditions
Catalyst characterisation, battery materials, industrial process monitoring
Target Verticals
Catalysis / chemicals (core published work)
Energy / batteries
Industrial process monitoring
Aerospace materials (likely, given DESY P07 access)
Their Differentiators
World-leading XRD-CT expertise — Vamvakeros pioneered the technique industrially
Open-source nDTomo software builds scientific credibility
RSC Prize and Royal Society Fellowship — high academic legitimacy
Diamond proximity — fastest UK access route
Weaknesses vs Us / Partnership Angle
XRD-CT only — very narrow technique portfolio
No Wavegate equivalent
UK-centric — limited continental European client base (inferred)
Strong partnership angle: they handle XRD-CT; we refer clients needing broader technique range
ESRF MXpress / NSLS-II Proprietary
Facility-run programmes — the status quo we replace
ESRF's mail-in MX service (running since 2002) and NSLS-II's proprietary industrial access at $790/hr. These are the programmes clients use before they find us. We offer the same data faster, with more expertise, under one contract.
Facility-runStatus quo to displace
ESRF MXpress
Running since2002 — the original industrial mail-in synchrotron service
TechniqueMacromolecular X-ray crystallography (MX) only
ProcessClient ships crystals by post; ESRF collects data remotely on ID23 / ID30 beamlines; data returned electronically
TurnaroundWeeks to months depending on queue and programme slot availability
PricingProprietary access pricing not publicly disclosed; academic MX access is free via proposal; industrial access is priced separately
Key contactAthanasios Papazoglou (Business Developer, ESRF) — see Contacts tab
NSLS-II Industrial / Proprietary Access
LocationBrookhaven National Lab, Upton, New York, USA
Pricing~$790/hr with 2-hour minimum; 100% advance payment required
TechniquesWide range across 28 beamlines: XRD, SAXS, imaging, spectroscopy, MX
ProcessDirect booking via proprietary access route; no competitive proposal required but full user safety training needed
Key contactJun Wang, Physicist Industrial Program Officer — junwang@bnl.gov / +1 (631) 344-2661
Why Clients Leave Facility Programmes and Come to Us
No experiment expertise included — client must know what they want and how to interpret results
Long lead times even on proprietary routes — scheduling around academic beam use
Complex legal agreements — facility user contracts with IP clauses require legal review
NSLS-II requires 100% advance payment and mandatory safety training — high friction for first-timers
Geography: NSLS-II is US-only; ESRF MXpress is pharma-only (MX technique)
Our advantage: one contract, full expertise, Wavegate speed, broader technique access across multiple European facilities
Key Contacts
Organized by category: facility liaisons, competitors, and prospects
LinkedIn URLs not directly confirmed unless stated. Names, titles, and emails sourced from official facility and company websites. Search LinkedIn by name + company for direct profile links.
| Name | Title | Facility | Contact | Notes |
|---|---|---|---|---|
| Dr. Sabine Brock | Deputy CTO, Head of Industry Relations | DESY Innovation & Technology Transfer | Search LinkedIn | Senior strategic contact. Presents DESY at trade fairs and builds industrial partnerships. Priority relationship. |
| Dr. Saiva Huck | Industry Cooperation, Photon Science | DESY | Search LinkedIn | Direct gatekeeper for PETRA III and PETRA IV industrial access. |
| Oliver Wendt | Manager Innovation Services, Business Development | DESY | oliver.wendt@desy.deSearch LinkedIn | Most accessible entry point at DESY. Named contact for industrial case studies. |
| Dr. Dirk Klugmann | Manager Innovation Services PETRA IV | DESY | Search LinkedIn | Developing PETRA IV industrial business cases. Forward-looking contact. |
| Dr. Nadja Kolpin | Platform Management Hi-Acts | DESY | Search LinkedIn | Central contact for Hi-Acts industry network at DESY. |
| Jun Wang | Physicist, Industrial Program Officer | NSLS-II, Brookhaven National Lab | junwang@bnl.gov+1 (631) 344-2661 | Named industrial liaison for all NSLS-II commercial access. Verified source. |
| Athanasios Papazoglou | Business Developer | ESRF, Grenoble | Search LinkedIn | Works directly with industrial clients at ESRF. Managed BASF STREAMLINE project. |
| Company | Name | Title | Contact | Notes |
|---|---|---|---|---|
| Scatterin AB | Ahmet Bahadir Yildiz | CEO & Co-founder | LinkedIn (confirmed) | KTH spinoff. Closest direct competitor to our model. Pre-booked beamtime + end-to-end service at DESY P07/P21.2, MAX IV, ISIS, ESS. |
| Scatterin AB | Prof. Peter Hedstrom | CSO & Co-founder | LinkedIn (confirmed) | KTH Professor; Director of CeXS and NEXT competence centre. Scientific credibility anchor for Scatterin. Strong facility relationships at DESY and MAX IV. |
| Momentum Transfer | Dr. Sebastian Winkler | CEO & Co-founder | Search LinkedIn | Synchrotron veteran. Emerging direct competitor at DESY P25. Watch closely. |
| Momentum Transfer | Dr. Bernd Hinrichsen | CSO & Co-founder | LinkedIn (confirmed) | 13 yrs at BASF (XRD/SEM/TEM/NMR labs). Left to co-found Momentum Transfer. Strongest public signal of industrial demand for our market. |
| Finden Ltd | Antony Vamvakeros | R&D Lead Scientist; Royal Society Industry Fellow | LinkedIn (confirmed) | XRD-CT pioneer, 2023 RSC Horizon Prize. Uses DESY PETRA III P07. Potential partner for XRD-CT referrals. |
| SARomics Biostructures AB | Bjorn Walse | CEO & Co-founder | Search LinkedIn | Pharma-only structural CRO. Founded 2006 at MAX II. US expansion via Accelero Biostructures (Apr 2026). Partnership angle: they do pharma MX, we do everything else. |
| Proteros Biostructures GmbH | Dr. Torsten Neuefeind | CEO & Founder | LinkedIn (confirmed) | Largest pharma structural CRO in Europe. 18/20 Big Pharma clients. PE-owned (Inflexion). Potential overflow/white-label partner for pharma MX. |
Budget Holder = signs off on spend. Champion = uses the data, can build internal case. Technical = end user, not a buyer. Find Contact = no named person yet, LinkedIn search ready.
| Company | Named Contact + Title | Role | Vertical | Status | Website | Pitch Angle | Who to Contact | |
|---|---|---|---|---|---|---|---|---|
| Pharma & Life Sciences | ||||||||
| BioNTech SE | Heinrich Haas Senior Scientist / R&D | Champion | Pharma / mRNA | Warm | biontech.com | H. Haas | Ugur Sahin personally co-authored SAXS study at PETRA III P12. Beamtime is embedded in their R&D pipeline. | Contact Haas as technical champion. Budget holder: Head of Structural Biology / VP R&D. |
| Idorsia Pharmaceuticals | Daniel Ritz Senior Director of Biology | Budget Holder | Pharma / Drug Discovery | Warm | idorsia.com | Search LinkedIn | Used ESRF ID23-1 for COVID drug discovery. Publicly quoted — high-quality named outreach target. | Direct outreach to Ritz. Senior Director = budget authority. Use the ESRF ID23-1 work as the opener. |
| leadXpro AG | Robert Kin Yip Cheng Head of Biochemistry | Champion | Pharma / Membrane Proteins | Warm | leadxpro.com | Search LinkedIn | PSI spin-out. Ran the first-ever industrial serial crystallography on ESRF ID29 (Feb 2026). | Cheng is the right technical entry. Small company — CEO approves budget. Build the case through Cheng first. |
| AstraZeneca | Helena Kack, Tove Sjogren Scientists, Structural Biology (Gothenburg) | Technical | Pharma / Drug Discovery | Pipeline | astrazeneca.com | H. Kack T. Sjogren | ~800 structures/year. May outsource overflow or specialist runs. | Kack and Sjogren are technical users, not buyers. Budget held by Head of Structural Biology or VP Drug Discovery, Gothenburg. Use them as champions. |
| CrystalsFirst | Serghei Glinca Founder and CEO | Budget Holder | Pharma / Drug Discovery | Warm | crystalsfirst.com | Search LinkedIn | Active DESY P11 partnership for fragment-based drug discovery. Potential partner or client. | Founder/CEO = budget holder and decision maker in one. Accessible startup contact. Direct outreach. |
| GSK | No named contact yet Find: Head of Structural Biology | Find Contact | Pharma | Pipeline | gsk.com | Search LinkedIn | Confirmed Diamond Light Source industrial user. | Find Head of Structural Biology or Protein Sciences — that person manages the synchrotron relationship. Budget held by VP Drug Discovery. |
| Aerospace & Defence | ||||||||
| Rolls-Royce | David Rugg Senior Fellow, Materials | Champion | Aerospace / Turbines | Warm | rolls-royce.com | Search LinkedIn | Used Diamond I12 for Trent 1000 turbofan blade XRD. First industrial user of the JEEP beamline. | Rugg is the champion but not the buyer. Budget held by VP Materials / Director of Advanced Technology. Use Rugg to escalate. |
| GKN Aerospace | No named contact yet Find: Head of Materials Characterisation | Find Contact | Aerospace / Composites | Warm | gknaerospace.com | Search LinkedIn | Confirmed DESY PETRA III user. Same data, less friction, faster turnaround. | No named contact yet. Search LinkedIn for Head of Materials Science or Advanced Characterisation. Budget holder: VP Engineering / Director of Materials Technology. |
| Airbus | Cecile Weulersse Radiation/SEE Test Engineer, 20+ yrs | Technical | Aerospace / Space Systems | Pipeline | airbus.com | Search LinkedIn | Used ESRF ID09 for satellite chip radiation/SEE testing. | Weulersse is the technical user, not the buyer. Budget held by Radiation Test Programme Manager or VP Space Systems. Use her as a reference entry point. |
| Energy & Chemicals | ||||||||
| Johnson Matthey | Dr Elizabeth Rowsell OBE CTO | Budget Holder | Energy / Fuel Cells | Warm | matthey.com | Search LinkedIn | Drove JM's Diamond I14 investment for platinum group metals and hydrogen fuel cells. | CTO = budget holder. Highest-level warm entry in the dataset. Direct outreach appropriate. |
| BASF SE | No named contact yet Find: Head of XRD / Advanced Characterisation, Ludwigshafen | Find Contact | Chemicals / Catalysis | Pipeline | basf.com | Search LinkedIn | Co-designed ESRF STREAMLINE powder diffraction service. Hinrichsen left to found Momentum Transfer — his replacement holds the relationship. | Find new Head of Advanced Characterisation in Ludwigshafen. Budget held by VP Corporate Research. |
| Siemens Energy | No named contact yet Find: Head of Materials R&D or Advanced Manufacturing | Find Contact | Energy / Turbines | Pipeline | siemens-energy.com | Search LinkedIn | Turbine blade and high-temperature alloy characterisation. In-situ strain measurement under service conditions is the key use case. | Find Head of Advanced Materials or VP R&D Turbines. Budget held at VP level. |
| Topsoe | No named contact yet Find: Head of Catalysis Characterisation | Find Contact | Chemicals / Catalysts | Pipeline | topsoe.com | Search LinkedIn | Confirmed DESY PETRA III user for XAS/XRD catalyst characterisation. | Find the person managing external characterisation experiments. Budget held by VP R&D / Head of Catalysis. |
| Automotive & Advanced Manufacturing | ||||||||
| TRUMPF | Dr. Mauritz Moller Automotive Industry Manager | Champion | Automotive / Laser Mfg | Warm | trumpf.com | Search LinkedIn | Used DESY P07 for in situ X-ray of EV copper welding. Publicly quoted. | Moller is the right first contact. Budget held by VP Advanced Manufacturing R&D. Use Moller to reach the buyer. |
| BMW Group | No named contact yet Find: Head of Battery Cell Characterisation or Materials R&D | Find Contact | Automotive / Battery | Pipeline | bmwgroup.com | Search LinkedIn | Known synchrotron user for battery cell and lightweight materials research. | Find Head of Battery Cell Characterisation or Materials R&D. Budget held by VP Battery Technology. |
| Verkor | Benoît Lemaignan CEO & Co-founder | Budget Holder | Automotive / EV Battery | Pipeline | verkor.com | B. Lemaignan | French EV battery startup building a 16 GWh gigafactory in Dunkirk. €2B+ funded. R&D centre near Grenoble — ESRF is on the doorstep. Operando XRD/XAS essential for NMC cathode and solid-state electrolyte development. | Lemaignan is CEO but find CTO or Head of Cell R&D for technical entry. ESRF proximity makes the pitch immediate — no long travel or logistics friction. |
| Volkswagen PowerCo | No named contact yet Find: Head of Cell Chemistry or Materials Characterisation | Find Contact | Automotive / EV Battery | Pipeline | volkswagen-powerco.com | Search LinkedIn | VW's dedicated battery subsidiary building 6 gigafactories across Europe. Operando synchrotron XRD/XAS is essential for cell chemistry R&D and process qualification at scale. | Find Head of Cell Chemistry or Advanced Characterisation. Budget held by CTO PowerCo. Large org — technical champion entry first, then escalate. |
| Semiconductors & Electronics | ||||||||
| STMicroelectronics | Philipp Hans Researcher, Materials Physics | Technical | Semiconductors | Pipeline | st.com | Search LinkedIn | 3 published ESRF ID01 studies (2022–2025) on phase-change memory. Active and recurring beamtime user. | Hans is the user, not the buyer. Budget held by Director of Advanced Characterisation or VP R&D. Reach Hans first, then escalate to his department head. |
| TSMC Dresden | No named contact yet Find: Head of Process R&D or Materials Engineering, Dresden | Find Contact | Semiconductors / Advanced Nodes | Pipeline | tsmc.com | Search LinkedIn | First TSMC fab in Europe, opening ~2027. €10B investment. Unlike Taiwan, no NSRRC equivalent nearby. Process qualification at advanced nodes requires XRD, XRR, SAXS. DESY Hamburg is ~600km away. | Fab is in qualification phase 2025-2027 — highest characterisation need is now. Find Head of Process Integration or Materials Engineering in Dresden. Budget held by VP Technology Europe. |
| Infineon Technologies | No named contact yet Find: Head of Advanced Process R&D, Dresden | Find Contact | Semiconductors / Automotive Chips | Pipeline | infineon.com | Search LinkedIn | Expanding Smart Power Fab in Dresden for automotive power electronics. EV drivetrain and SiC chip demand driving scale-up. Thin film XRD and XRR essential for power device process control. | Find Head of Materials Characterisation or Process R&D at Dresden fab. Budget held by VP R&D / Head of Frontend Manufacturing. |
| Bosch | No named contact yet Find: Head of Materials R&D, Semiconductor Division or Hydrogen R&D | Find Contact | Semiconductors + Energy / Hydrogen | Pipeline | bosch.com | Search LinkedIn | Operating automotive chip fab in Dresden (opened 2021). Also developing hydrogen electrolysis technology. Dual characterisation need: semiconductor process control (XRD/XRR) + catalyst XAS for hydrogen R&D. | Two separate entry points: semiconductor division (Dresden fab) and hydrogen/fuel cell R&D. Budget held at VP level in each division. Two-angle approach recommended. |
| Consumer | ||||||||
| Beiersdorf AG | Thomas Blatt Principal Scientist; DESY Foundation Council | Champion | Consumer / Cosmetics | Warm | beiersdorf.com | Search LinkedIn | Used PETRA III P06 XRF. On DESY Foundation Council — best-connected warm lead in Hamburg. | Blatt can champion internally. Budget holder: VP R&D / Head of Advanced Analytics. |
Sources
All research sources organized by category. Data collected June 2026 via automated web research.
Market SizingReports used for global market value, CAGR, and vertical breakdown figures.
| Source | Key Data Point | Link |
|---|---|---|
| Data Horizzon Research | Global synchrotron market $1.5B (2024) to $3.2B (2033), CAGR 9.2% | View report |
| Verified Market Reports | Corroborating $1.5B (2025) to $3.2B (2034) figures | View report |
| Future Market Insights | Instrumentation $1.2B to $2.0B, CAGR 5.6%; Oil & Gas 36.9%, Electronics 18.1%, Semiconductors 16.7% | View report |
| UKRI / ESRF Impact Evaluation (2023) | ~5% of ESRF users from industry (2011-2021); pain points documented | View PDF |
| NSLS-II Proprietary Research Policy | $790/hr FY2026; 100% advance payment; 2-hour minimum | View PDF |
| NSLS-II Industry Workshop Report (2020) | Documented barriers: unfamiliarity, no expertise, long lead times, cost, legal concerns | View PDF |
Industrial Users — ESRFNamed individuals and case studies from ESRF facility publications.
| Source | Contacts / Data | Link |
|---|---|---|
| ESRF: Idorsia drug discovery | Daniel Ritz and Julien Hazemann — SARS-CoV-2 Mpro inhibitor at ID23-1 | View article |
| ESRF: Airbus satellite chip testing | Cecile Weulersse — pulsed X-ray SEE testing of 3D stacked memory, ID09 | View article |
| ESRF: First industrial serial crystallography on ID29 (2026) | Robert Kin Yip Cheng (leadXpro AG) — membrane protein drug discovery | View article |
| Wiley: In Situ XRD on GST (STMicro, 2022) | Philipp Hans, Yannick Le-Friec, Roberto Simola — phase-change memory at ESRF ID01 | View paper |
| PMC: Macromolecular crystallography (AstraZeneca) | Helena Kack and Tove Sjogren — ~800 protein-ligand structures/year | View paper |
| PMC: How ESRF helps industry (2013) | Edward P. Mitchell (Business Development, ESRF) | View paper |
Industrial Users — DESY PETRA IIINamed individuals and case studies from DESY innovation pages and publications.
| Source | Contacts / Data | Link |
|---|---|---|
| PMC: BioNTech mRNA nanoparticle SAXS study | Ugur Sahin, Heinrich Haas, Sara Nogueira — SAXS at PETRA III P12 | View paper |
| DESY Innovation: Beiersdorf CoQ10 study | Thomas Blatt (Principal Scientist + DESY Foundation Council) — XRF at P06 | View article |
| DESY Innovation: CrystalsFirst partnership | Serghei Glinca (CEO) — fragment-based drug discovery at P11 | View article |
| TRUMPF press release: e-car laser welding | Dr. Mauritz Moller (Automotive Industry Manager) — in situ X-ray at P07 | View article |
| PETRA IV Campaign Start: BASF | Bernd Hinrichsen (Manager Research, BASF) — PETRA IV industrial panel | View article |
| DESY Innovation: Industrial case studies index | GKN Aerospace, OHB, Hilti, BioNTech, Captor, Haldor Topsoe, SKF, Beiersdorf confirmed | View index |
Industrial Users — Diamond Light SourceNamed individuals from Diamond industrial case studies (Harwell, UK).
| Source | Contacts / Data | Link |
|---|---|---|
| Diamond: Rolls-Royce fan blade case study | David Rugg (Senior Fellow for Materials) — in situ XRD at I12 | View case study |
| Johnson Matthey / Diamond I14 investment (2023) | Dr Elizabeth Rowsell OBE (CTO) — platinum group metals for hydrogen fuel cells | View article |
| Diamond: Engineering case studies index | Rolls-Royce, GSK, Unilever mentioned as industrial users | View index |
CompetitorsSources for commercial beamtime service providers.
| Source | Key Data | Link |
|---|---|---|
| Scatterin AB website | Pre-booked beamtime, 1-2 week delivery, lab-comparable pricing | View site |
| Momentum Transfer website | Co-founders Winkler, Hinrichsen (ex-BASF), Terban | View team |
| Antony Vamvakeros LinkedIn (Finden Ltd) | R&D Lead, XRD-CT at DESY P07; direct LinkedIn confirmed | View profile |
| NSLS-II Industry page | Jun Wang contact; access modes (general, proprietary, rapid) | View page |